CD20 is expressed in about one half of pediatric acute lymphoblastic leukemia (ALL) cases with B-cell precursor (BCP) origin. We observed recently that it is further upregulated in some patients during induction treatment. To understand the impact of this on the potential effectiveness of anti-CD20 immunotherapy, we studied 237 CD10-positive pediatric BCP-ALL patients consecutively recruited to trial AIEOP-BFM-ALL-2000. We analyzed CD20 expression changes from diagnosis to end-induction, focusing on sample pairs with ≥ 0.1% residual leukemic blasts (MRD), and assessed complementinduced cytotoxicity by CD20-targeting with rituximab in-vitro (n=9 paired samples).
Introduction
CD20 is a signature B-cell differentiation antigen strongly expressed on the surface of mature normal as well as malignant B-cells. It is also expressed, but at lower levels and with larger variance, on more immature B-cells and their malignant counterparts found in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). 1, 2 In line with the expression patterns anti-CD20 directed immunotherapy has been shown to elicit potent anti-tumor effects specifically in mature B-cell lymphoma and leukemia, where it has been incorporated into standard treatment as a valuable therapy advance. 3 To date, the most broadly evaluated compound for CD20-targeting is rituximab, a chimeric antibody that was licensed by the FDA in 1997 as the first anticancer monoclonal antibody. It acts by complement-dependent and antibody-dependent cell-mediated cytotoxicity, as well as by inducing apoptosis directly. 4 Recently, targeted therapy with rituximab has been implicated also in BCP-ALL for combination with conventional chemotherapy, 5 with at least six active trials listed at http://www.clinicaltrials.gov/ as per May 2008. In children with BCP-ALL, published usage has been confined mostly to anecdotal reports on relapsed or refractory disease. [6] [7] [8] [9] Importantly, activity can be anticipated primarily in CD20-positive cases which relevantly limits its applicability in pediatric BCP-ALL supposedly to less than one half of patients as determined at diagnosis. 2 During the course of an internationally collaborative study on flow cytometric minimal residual disease (MRD) assessment in childhood ALL, we noted that phenotypic modulation occurred regularly in viable leukemic cells resisting induction treatment with protocol AIEOP-BFM 2000. 10, 11 As one of the most frequently observed phenotypic changes, CD20 expression was found to be up-regulated. Gene expression analysis
For personal use only. on May 4, 2017 . by guest www.bloodjournal.org From showed that this increase in surface protein density is paralleled by up-regulation of mRNA expression as early as at day 8 after start of treatment. 12 The phenomenon has largely been attributed to glucocorticoid action. 11, 12 We hypothesized that this increase in CD20 expression could be exploited for anti-CD20 targeted therapy, setting the stage that more patients with BCP-ALL than assessable upon phenotypic analysis at diagnosis could eventually profit from such treatment. To get a more comprehensive view of the frequency and the potential impact of CD20 up-regulation, we analyzed this in a large cohort of pediatric BCP-ALL patients recruited to a nation-wide treatment protocol in Austria and also assessed the effects of rituximab in paired in-vitro analyses.
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Materials and methods

Patients, samples, and treatment
Between December 2000 and June 2006, 306 patients with ALL (age 1 -18 years) were consecutively recruited in Austria to the international treatment trial AIEOP-BFM ALL 2000 (registered at http://www.clinicaltrials.gov/ as NCT00430118). 13 Flow cytometric MRD assessment was done in these patients in the Vienna laboratory as part of a 4-center collaborative add-on study. Sampling for immunophenotypic and MRD investigations was approved along with the international trial by the institutional ethical committees, and was strictly done according to informed consent guidelines in accordance with the Declaration of Helsinki. In assessing CD20 expression we focused on the 237 cases with a CD10-positive BCP phenotype where we obtained enough material for analysis, thus excluding from further analysis 38 patients with T-ALL, 12 with a pro-B phenotype, and 19 with inadequate sample. Peripheral blood (PB) and bone marrow (BM) samples were investigated for this study at diagnosis and from several follow-up time-points during induction treatment: PB day 8, BM from days 15 and 33.
Induction treatment consisted of a 7-day pre-phase with daily oral prednisolone (60 mg/m 2 body-surface-area/day) and one dose of intrathecal methotrexate (age-adjusted).
From day 8 until day 33, patients received a four-drug regimen containing randomized glucocorticoids (prednisolone 60 mg/m 2 or dexamethasone 10 mg/m 2 ), 8 infusions of Lasparaginase, four administrations of daunorubicin and vincristine, as well as additional intrathecals. 13 Glucocorticoid medication was tapered after day 28. A second induction phase was started not earlier than on day 36.
Data on genotype, clinical risk stratification (low-, medium-, and high-risk) and outcome were retrieved from the Austrian ALL-BFM 2000 study office.
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Flow cytometry
The standardized procedure has been recently described in detail including sample preparation, description of the entire antibody panel, stain-lyse procedure, and flow cytometric analysis.
14 A fixed quadruple-stain was used to investigate CD20 expression:
CD20/CD10/CD19/CD34, (ordered by channel 1 to 4: fluorescein isothiocyanate, FITC;
phycoerythrin, PE; phycoerythrin-cyanin 7, PE-Cy7; allophycocyanin, APC). In experiments assessing differences in CD20 expression between viable and apoptotic blast cells, an Annexin V-staining reagent (Becton Dickinson; BD) was substituted for CD34 in channel 4. 11 The instrument set-up was optimized daily by analyzing Calibrite™ beads (BD) and normal adult peripheral blood (PB) cells stained with
Immunophenotyping at diagnosis and quality control evaluations were performed collecting at least 30 000 cellular events, while for MRD measurements 300 000 events were acquired from 700 000 stained cells. Cell acquisition was performed with a FACSCalibur™ cytometer (BD) using the CELL Quest™ software (BD). Data analysis was done with the PAINT-A-GATE™ software (BD). Leukemic cells were identified using an immunological gate (associated with 90°-scattering, SSC) which included all CD19-positive cells. Minimal residual disease was defined as an accumulation of at least 10 clustered events displaying lymphoid scattering properties and leukemia-associated immunophenotypic characteristics as reported. 
Rituximab experiments
Paired BM samples from 9 patients from diagnosis and follow-up time-points during induction were selected for these experiments according to a negative/dim CD20-expression status at diagnosis, and to obvious CD20 up-regulation (various degrees) as well as sufficient MRD proportions at follow-up (≥1% 
Statistical analyses
Concordance and correlations between sample cohorts or time-points were estimated using either the Shrout-Fleiss reliability assay or the Pearson correlation coefficient Hence, all follow-up samples with very low or even negative MRD and their counterparts from diagnosis were excluded from further analyses. As compared to the total available sample cohort at diagnosis, those with paired follow-up samples had very similar proportions of CD20-positive cases at diagnosis (BM: 45%; PB: 52%).
Follow-up specimens showed significantly increased CD20 expression when compared to their paired initial samples (Table 1 ). This up-modulation was seen as an overall increase in CD20-positive samples as early as at day 8 in PB (75% positive; cPB0/8: p<0.001), and also in follow-up BM samples (day 15: 71% positive, cBM0/15: p<0.001; day 33: 81%, cBM0/33 p<0.01). There was even a trend towards a further increase from
For personal use only. on May 4, 2017. by guest www.bloodjournal.org From day 15 to day 33 (cBM15/33 p=0.05; n=25 pairs). The mean proportion of CD20 pos blasts in BM was 25% at day 0 (±28% SD), rose to 47% at day 15 (±34%), and to 72% at day 33 (±36%). Regarding fluorescence levels, CD20 expression of blasts increased from a mean MFI-value of 14 in initial samples (±27 SD) to 45 (±100) at day 15, and to 109 (±187) at day 33. Only 5.7% of patients had a CD20-MFI > 50 at diagnosis, but the proportion increased to 22.2% at day 15 and to 48% at day 33. 
CD20 expression in sub-groups of patients
The two patient cohorts receiving different glucocorticoids (days 8 until 33) upon initial randomization were very similar in CD20 expression at baseline, and also reacted similar as estimated at day 15 and day 33 in BM (p=not significant).
There was no significant correlation between CD20 expression and age (as tested in groups of 1 -5, 6 -10, and >10 years) or ALL-phenotype (C-vs. preB-subtype). In addition, we found no significant difference in CD20 expression in BM samples between the three BFM risk groups (Table 1) , neither at diagnosis (p=0.06) nor at day 15 (p=0.32). CD20 up-regulation occurred in follow-up in all three BFM risk groups (p<0.001
for each risk group), with high-risk patients showing very high proportions of positive cases at all time-points (83-88%).
TEL/AML1-rearranged cases (n=46) showed significantly lower CD20 expression in BM samples both at diagnosis and day 15 compared to the complementary cohort (n=113;
p<0.01 for all correlations), as reflected by the number of CD20-positive cases ( Non-TEL/AML1//non-hyperdiploid samples (n=74) had higher CD20 values than TEL/AML1 cases in all items both at diagnosis and day 15 (p<0.01 in all correlations), but were not significantly different in similar comparisons from hyperdiploid cases. CD20
was up-regulated during induction both in TEL/AML1 and non-TEL/AML1 patients (p<0.01 for both; Table 1 ), but the former reached lower positivity (in 46-56% of cases)
than the latter (81-85%).
Fourteen patients of the cohort of 159 had a relapse within a median observation period of 4.5 years. There was no significant correlation between the relapse status and CD20
expression of leukemic cells from BM, neither at diagnosis (p=0.17) nor at day 15 (p=0.32). Of the 14 relapse cases only four were CD20-positive initially as compared to 11 at day 15. The mean proportions of CD20 pos blasts increased from 13% (±15% SD) at diagnosis to 44% (±28% SD) at day 15. The three relapsed patients, who were included in the group of 27 with high MRD also at day 33, had 75% (mean; ±17% SD) CD20 pos blasts at this time-point.
CD20 up-regulation enhances rituximab-inducible complement-lysis
In 9 sample pairs of BM from diagnosis and follow-up we tested whether CD20 upregulation is strong and specific enough to translate into relevant complementdependent cytolysis induced by rituximab in in-vitro incubation. There were sufficient leukemic cells in these follow-up samples to do the test reliably (mean MRD-proportion 17.9% ±21.6% SD). The selected sample pairs showed low CD20 expression at diagnosis (mean MFI 20 ±12 SD) and significantly higher levels at follow-up (mean MFI Figure 2 , rituximab induced significantly more efficient cytolysis in follow-up samples (mean recovery 39% ±67% SD) than in initial specimens (mean recovery 82% ±23% SD; p<0.05 for difference). Stronger cytolysis was seen in all samples with CD20 MFI >50 as compared to those with lower MFI values ( Figure 3A ). Furthermore, we tested whether rituximab-action could be augmented by neutralizing the complement-regulatory proteins CD55 and CD59. Using blocking antibodies to these antigens in six sample pairs, the "augmented" lysis was slightly more efficient than rituximab-lysis alone in 11 of the 12 samples investigated (mean recovery 40% ±36% versus 51% ±38% SD; p=0.01; Figure 3B ).
CD20 expression is modulated by prednisolone in-vitro
We incubated 10 initial ALL samples with various concentrations of prednisolone for three days and assessed thereafter the CD20 expression levels on viable ( The first is that leukemic cells can be influenced to alter their cellular processes and to acquire qualities exploitable for their eradication. There is now sufficient evidence to consider that leukemic phenotypes (of individual clonal cases) are not stable but may vary within certain limits upon outer influences. 10, 11, 24 In this respect, these changes in leukemia phenotypes may well be considered just as surrogate appearance of the cellular processes in general. 12 This property could be deployed for future treatment specifically in cases where certain sub-cellular pathways, as e.g. those leading to apoptosis, are blocked or insufficient, so that leukemia could be tackled via alternative routes. Importantly, we found that in particular high-risk BCP-ALLs (which include those with a poor glucocorticoid response or even with a poor response to a four-drug induction) were CD20-positive in follow-up in 83% of cases. More generally, 81% of all patients with significant MRD after induction (≥0.1%), an amount known to correlate with dismal outcome, 16 were CD20-positive even at quite high levels of intensity (day 33:
mean MFI 109 ±187 SD). In the in-vitro experiments we found efficient cytolysis only when CD20 expression intensities surpassed a MFI value of 50. This corresponds in our system roughly to The second important aspect is that this intervention, which influences the leukemic cellular processes in a way that blast cells acquire qualities exploitable for their eradication, comes along without a need for any extra medication. The process seems to be induced by the induction chemotherapy for ALL, and since obvious as early as at day 8 of therapy (after one week of prednisolone and a single intrathecal methotrexate instillation) most probably is triggered in this phase by glucocorticoids.
12 This is corroborated by our finding that CD20 is up-modulated by prednisolone incubation invitro, an effect which we found to be non-uniform and patient-specific. We are aware that after the prednisolone-pre-phase, also other medications may add to the observed effect. Other substances than steroids have already been shown to influence CD20 expression. For example, bryostatin-1, a protein kinase C modulator, enhances both CD20 mRNA and protein levels, and a combined therapy with rituximab was suggested recently. 28 In cell line experiments this effect was found to be even insensitive to steroid action. Such effects add to strategies aiming at enhancing anti-CD20 directed Since up-regulation of CD20 is induced during chemotherapy (most obviously due to glucocorticoid action) without a need for extra medication, this is a simple and straightforward way to influence leukemic cells so that they acquire qualities exploitable for their eradication. Based on this rationale, clinical trials in pediatric ALL could now be designed to assess whether rituximab would result in a clinical benefit. We also thank G. Fröschl (Vienna) for excellent technical assistance. 
